Abstract
Background: The traditional treatment of venous thromboembolism (VTE) with heparin and warfarin has numerous limitations. New oral anticoagulants represent the promising alternative with the potential to overcome the limitations of traditional treatment.
Objective: Apixaban is an oral factor Xa inhibitor with a rapid onset of action and predictable pharmacokinetics that allows a fixed dose regimen. With this characteristic apixaban overcomes many limitations and simplifies treatment of VTE eliminating the need for initial parenteral anticoagulant therapy and laboratory monitoring.
Results: Fixed-dose regimen of oral apixaban alone is as effective as conventional treatment regimen and is associated with a clinically relevant reduction of major bleeding. Extended anticoagulation with apixaban with either a treatment dose (5 mg twice daily) or thromboprophylactic dose (2.5 mg twice daily) reduces the risk of recurrent venous thromboembolism without increase in the rate of major bleeding.
Conclusion: Therefore, apixaban provides a simple, effective and safe alternative to conventional acute or long-term treatment of VTE.
Keywords: Bleeding complications, management, new oral anticoagulants, venous thrombosis.
Current Drug Targets
Title:Deep Vein Thrombosis and Pulmonary Embolism in the Apixaban Era: From Bench to Bedside
Volume: 19 Issue: 6
Author(s): Pavel Poredos*Mateja Kaja Jezovnik
Affiliation:
- Department of Vascular Disease, University Medical Centre, Ljubljana,Slovenia
Keywords: Bleeding complications, management, new oral anticoagulants, venous thrombosis.
Abstract: Background: The traditional treatment of venous thromboembolism (VTE) with heparin and warfarin has numerous limitations. New oral anticoagulants represent the promising alternative with the potential to overcome the limitations of traditional treatment.
Objective: Apixaban is an oral factor Xa inhibitor with a rapid onset of action and predictable pharmacokinetics that allows a fixed dose regimen. With this characteristic apixaban overcomes many limitations and simplifies treatment of VTE eliminating the need for initial parenteral anticoagulant therapy and laboratory monitoring.
Results: Fixed-dose regimen of oral apixaban alone is as effective as conventional treatment regimen and is associated with a clinically relevant reduction of major bleeding. Extended anticoagulation with apixaban with either a treatment dose (5 mg twice daily) or thromboprophylactic dose (2.5 mg twice daily) reduces the risk of recurrent venous thromboembolism without increase in the rate of major bleeding.
Conclusion: Therefore, apixaban provides a simple, effective and safe alternative to conventional acute or long-term treatment of VTE.
Export Options
About this article
Cite this article as:
Poredos Pavel*, Jezovnik Kaja Mateja, Deep Vein Thrombosis and Pulmonary Embolism in the Apixaban Era: From Bench to Bedside, Current Drug Targets 2018; 19 (6) . https://dx.doi.org/10.2174/1389450116666150518100106
DOI https://dx.doi.org/10.2174/1389450116666150518100106 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Platelet Protein Synthesis and Translational Control
Current Proteomics Criteria for Creating and Assessing Mouse Models of Diabetic Neuropathy
Current Drug Targets Periodontal Disease and Periodontal Tissue Regeneration
Current Stem Cell Research & Therapy Renal COX-2, Cytokines and 20-HETE: Tubular and Vascular Mechanisms
Current Pharmaceutical Design In Vivo Imaging of the Diseased Nervous System: An Update
Current Pharmaceutical Design Mechanisms for Targeted Delivery of Nanoparticles in Cancer
Current Pharmaceutical Design Sirolimus Eluting Stent: A New Era in Interventional Cardiology?
Current Pharmaceutical Design Immunomodulatory Plant Natural Products as Therapeutics against Inflammatory Skin Diseases
Current Topics in Medicinal Chemistry Perioperative Management of Obese Parturients
Current Women`s Health Reviews Polyphenols: Potential Future Arsenals in the Treatment of Diabetes
Current Pharmaceutical Design Polyphenols-Rich Natural Products for Treatment of Diabetes
Current Medicinal Chemistry Preventing Activation of Receptor for Advanced Glycation Endproducts in Alzheimers Disease
Current Drug Targets - CNS & Neurological Disorders The Pragmatism of Polyphenols and Flavonoids Application as Drugs, from an Academic Lab to a Pharmacy Shelf
Current Pharmaceutical Design Enhanced Activity of pSTAT-3 Ser-727 in Functional Endothelial Cells Under Calcifying Conditions
Current Chemical Biology Editorial [Hot Topic: Perspectives in Integrin Blocking (Executive Editor: C. Marcinkiewicz)]
Current Pharmaceutical Design The Heme Oxygenase System: Its Role in Liver Inflammation
Current Drug Targets - Cardiovascular & Hematological Disorders Patent Selections
Recent Patents on Cardiovascular Drug Discovery microRNAs: Promising Biomarkers and Therapeutic Targets of Acute Myocardial Ischemia
Current Vascular Pharmacology Involvement of the Transforming Growth Factor β in the Pathogenesis of Hereditary Hemorrhagic Telangiectasia
Current Pharmaceutical Design The Role of Nicotinamide Phosphoribosyltransferase in Cerebral Ischemia
Current Topics in Medicinal Chemistry